Eric E Abrahamson1, Jeffrey S Stehouwer2, Alberto L Vazquez2, Guo-Feng Huang2, N Scott Mason2, Brian J Lopresti2, William E Klunk3, Chester A Mathis2, Milos D Ikonomovic4. 1. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA. 2. Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA; Department of Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA. Electronic address: ikonomovicmd@upmc.edu.
Abstract
INTRODUCTION: Positron emission tomography (PET) using radiolabeled amyloid-binding compounds has advanced the field of Alzheimer's disease (AD) by enabling detection and longitudinal tracking of fibrillar amyloid-β (Aβ) deposits in living people. However, this technique cannot distinguish between Aβ deposits in brain parenchyma (amyloid plaques) from those in blood vessels (cerebral amyloid angiopathy, CAA). Development of a PET radioligand capable of selectively detecting CAA would help clarify its contribution to global brain amyloidosis and clinical symptoms in AD and would help to characterize side-effects of anti-Aβ immunotherapies in AD patients, such as CAA. METHODS: A candidate CAA-selective compound (1) from a panel of analogues of the amyloid-binding dye Congo red was synthesized. The binding affinity to Aβ fibrils and lipophilicity of compound 1 were determined and selectivity for CAA versus parenchymal plaque deposits was assessed ex-vivo and in-vivo in transgenic APP/PS1 mice and in postmortem human brain affected with AD pathology. RESULTS: Compound 1 displays characteristics of Aβ binding dyes, such as thioflavin-S, in that it labels both parenchymal Aβ plaques and CAA when applied to histological sections from both a transgenic APP/PS1 mouse model of Aβ amyloidosis and AD brain. Thus, compound 1 lacks molecular selectivity to distinguish Aβ deposits in CAA from those in plaques. However, when administered to living APP/PS1 mice intravenously, compound 1 preferentially labels CAA when assessed using in-vivo two-photon microscopy and ex-vivo histology and autoradiography. CONCLUSION: We hypothesize that selectivity of compound 1 for CAA is attributable to its limited penetration of the blood-brain barrier due to the highly polar nature of the carboxylate moiety, thereby limiting access to parenchymal plaques and promoting selective in-vivo labeling of Aβ deposits in the vascular wall (i.e., "delivery selectivity"). Published by Elsevier Inc.
INTRODUCTION: Positron emission tomography (PET) using radiolabeled amyloid-binding compounds has advanced the field of Alzheimer's disease (AD) by enabling detection and longitudinal tracking of fibrillar amyloid-β (Aβ) deposits in living people. However, this technique cannot distinguish between Aβ deposits in brain parenchyma (amyloid plaques) from those in blood vessels (cerebral amyloid angiopathy, CAA). Development of a PET radioligand capable of selectively detecting CAA would help clarify its contribution to global brain amyloidosis and clinical symptoms in AD and would help to characterize side-effects of anti-Aβ immunotherapies in AD patients, such as CAA. METHODS: A candidate CAA-selective compound (1) from a panel of analogues of the amyloid-binding dye Congo red was synthesized. The binding affinity to Aβ fibrils and lipophilicity of compound 1 were determined and selectivity for CAA versus parenchymal plaque deposits was assessed ex-vivo and in-vivo in transgenic APP/PS1 mice and in postmortem human brain affected with AD pathology. RESULTS: Compound 1 displays characteristics of Aβ binding dyes, such as thioflavin-S, in that it labels both parenchymal Aβ plaques and CAA when applied to histological sections from both a transgenic APP/PS1 mouse model of Aβ amyloidosis and AD brain. Thus, compound 1 lacks molecular selectivity to distinguish Aβ deposits in CAA from those in plaques. However, when administered to living APP/PS1 mice intravenously, compound 1 preferentially labels CAA when assessed using in-vivo two-photon microscopy and ex-vivo histology and autoradiography. CONCLUSION: We hypothesize that selectivity of compound 1 for CAA is attributable to its limited penetration of the blood-brain barrier due to the highly polar nature of the carboxylate moiety, thereby limiting access to parenchymal plaques and promoting selective in-vivo labeling of Aβ deposits in the vascular wall (i.e., "delivery selectivity"). Published by Elsevier Inc.
Authors: Lei Zhang; Anabella Villalobos; Elizabeth M Beck; Thomas Bocan; Thomas A Chappie; Laigao Chen; Sarah Grimwood; Steven D Heck; Christopher J Helal; Xinjun Hou; John M Humphrey; Jiemin Lu; Marc B Skaddan; Timothy J McCarthy; Patrick R Verhoest; Travis T Wager; Kenneth Zasadny Journal: J Med Chem Date: 2013-05-28 Impact factor: 7.446
Authors: Monica Garcia-Alloza; Elissa M Robbins; Sandy X Zhang-Nunes; Susan M Purcell; Rebecca A Betensky; Susan Raju; Claudia Prada; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch Journal: Neurobiol Dis Date: 2006-10-05 Impact factor: 5.996
Authors: M Edip Gurol; Gregory Dierksen; Rebecca Betensky; Christopher Gidicsin; Amy Halpin; Alex Becker; Jeremy Carmasin; Alison Ayres; Kristin Schwab; Anand Viswanathan; David Salat; Jonathan Rosand; Keith A Johnson; Steven M Greenberg Journal: Neurology Date: 2012-07-11 Impact factor: 9.910
Authors: Kim S Rutgers; Alexandra van Remoortere; Mark A van Buchem; C Theo Verrips; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch; Sjoerd G van Duinen; Marion L Maat-Schieman; Silvère M van der Maarel Journal: Neurobiol Aging Date: 2009-12-16 Impact factor: 4.673
Authors: Violetta N Pivtoraiko; Tamara Racic; Eric E Abrahamson; Victor L Villemagne; Benjamin L Handen; Ira T Lott; Elizabeth Head; Milos D Ikonomovic Journal: Front Aging Neurosci Date: 2021-08-13 Impact factor: 5.702
Authors: Vafa Alakbarzade; Jonathan Mr French; David R Howlett; Johannes Attems; Paul T Francis; Sarah Stratton; Camilla N Clark; Anthony C Pereira; Atticus H Hainsworth Journal: Alzheimers Dement (N Y) Date: 2021-02-16